Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 7/2019

01-07-2019 | Rectal Cancer | Colorectal Cancer

Longer Intervals from Neoadjuvant Therapy to Rectal Cancer Surgery: The Clock is Ticking…

Authors: Laura Melina Fernandez, MD, Rodrigo Oliva Perez, MD, PhD

Published in: Annals of Surgical Oncology | Issue 7/2019

Login to get access

Excerpt

After the widespread implementation of neoadjuvant multimodal treatment of rectal cancer, a critical issue during management of these patients has become the exact time interval between neoadjuvant treatment completion and definitive surgery. By the end of the last century, a single, randomized trial suggested that 6 weeks was the ideal interval after demonstrating superior response rates compared with 2 weeks from chemoradiation.1 …
Literature
1.
Francois Y, Nemoz CJ, Baulieux J, et al. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol. 1999;17(8):2396.CrossRefPubMed
2.
Garcia-Aguilar J, Chow OS, Smith DD, et al. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol. 2015;16(8):957–66.CrossRefPubMedPubMedCentral
3.
Kalady MF, de Campos-Lobato LF, Stocchi L, et al. Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancer. Ann Surg. 2009;250(4):582–9.PubMed
4.
Sloothaak DA, Geijsen DE, van Leersum NJ, et al. Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer. Br J Surg. 2013;100(7):933–9.CrossRefPubMed
5.
Garcia-Aguilar J, Smith DD, Avila K, et al. Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial. Ann Surg. 2011;254(1):97–102.CrossRefPubMed
6.
Kerr SF, Norton S, Glynne-Jones R. Delaying surgery after neoadjuvant chemoradiotherapy for rectal cancer may reduce postoperative morbidity without compromising prognosis. Br J Surg. 2008;95(12):1534–40.CrossRefPubMed
7.
Lefevre JH, Mineur L, Kotti S, et al. Effect of interval (7 or 11 weeks) between neoadjuvant radiochemotherapy and surgery on complete pathologic response in rectal cancer: a multicenter, randomized, controlled trial (GRECCAR-6). J Clin Oncol. 2016; 34:3773-80.CrossRefPubMed
8.
Roxburgh CS, Lynn P, Paty PB, et al. Role of the interval from completion of neoadjuvant therapy to surgery in postoperative morbidity in patients with locally advanced rectal cancer. Ann Surg Oncol. 2019 (in press).
9.
Chadi SA, Malcomson L, Ensor J, et al. Factors affecting local regrowth after watch and wait for patients with a clinical complete response following chemoradiotherapy in rectal cancer (InterCoRe consortium): an individual participant data meta-analysis. Lancet Gastroenterol Hepatol. 2018;3(12):825–36.CrossRefPubMed
10.
Dattani M, Heald RJ, Goussous G, et al. Oncological and survival outcomes in watch and wait patients with a clinical complete response after neoadjuvant chemoradiotherapy for rectal cancer: a systematic review and pooled analysis. Ann Surg. 2018;268(6):955–67.CrossRefPubMed
11.
12.
Perez RO, Habr-Gama A, Sao Juliao GP, et al. Optimal timing for assessment of tumor response to neoadjuvant chemoradiation in patients with rectal cancer: do all patients benefit from waiting longer than 6 weeks? Int J Radiat Oncol Biol Phys. 2012;84(5):1159–65.CrossRefPubMed
Metadata
Title
Longer Intervals from Neoadjuvant Therapy to Rectal Cancer Surgery: The Clock is Ticking…
Authors
Laura Melina Fernandez, MD
Rodrigo Oliva Perez, MD, PhD
Publication date
01-07-2019
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 7/2019
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-019-07343-6

Other articles of this Issue 7/2019

Annals of Surgical Oncology 7/2019 Go to the issue

ASO Author Reflections

ASO Author Reflections: An Optimal Biological Model for Successful Drug Discovery

Sarcoma

Defining Rupture in Gastrointestinal Stromal Tumor: Semantics and Prognostic Value

Pancreatic Tumors

A Single-Institution Validation Study of Lymph Node Staging By the AJCC 8th Edition for Patients with Pancreatic Head Cancer: A Proposal to Subdivide the N2 Category

Breast Oncology

Chemoprevention Uptake for Breast Cancer Risk Reduction Varies by Risk Factor

Thoracic Oncology

Influence of Neoadjuvant Therapy on Poor Long-Term Outcomes of Postoperative Complications in Patients with Esophageal Squamous Cell Carcinoma: A Retrospective Cohort Study

Health Services Research and Global Oncology

Educating Surgical Oncology Providers on Perioperative Opioid Use: Results of a Departmental Survey on Perceptions of Opioid Needs and Prescribing Habits